The hormonal contraceptives market includes a range of birth-control products such as oral pills, patches, injectable contraception, implants, vaginal rings, and hormonal IUDs. These methods are used worldwide to prevent pregnancy, regulate menstrual cycles, and manage conditions like acne and PCOS. Market growth is supported by rising awareness of reproductive health, expanding family planning programs, and the increasing adoption of long‑acting reversible contraceptives (LARCs) like implants and hormonal IUDs. Innovations in user-friendly formats and increasing access to over-the-counter options are enhancing accessibility and adherence. While North America remains a leader, regions like Asia-Pacific are experiencing strong growth thanks to rising population, urbanization, and healthcare investment.
According to Fortune Business Insights, the global hormonal contraceptives market size was valued at USD 16,866.1 million in 2020 and is expected to reach USD 24,330.1 million by 2027, exhibiting a CAGR of 5.4% during the forecast period (2020–2027). North America dominated the global market with a market share of 39.03% in 2019.
In May 2021, Pantarhei Bioscience secured European Commission approval for its new oral contraceptive, Estelle. With this approval, Estelle became available for marketing across all EU member states, reflecting regulatory confidence in newer formulations.